<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> is a common disease that is usually detected at an advanced stage, because early-stage <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> is mostly asymptomatic and appropriate serologic biomarkers have not been established </plain></SENT>
<SENT sid="1" pm="."><plain>We have previously identified dermokine (DK) as a <z:chebi fb="7" ids="16670">peptide</z:chebi> secreted by keratinocytes and we found that DK-β/γ was expressed in <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, we focused on DK-β/γ as a new candidate diagnostic serum marker for early <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: DK-β/γ expression in human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell lines and tissues was assessed by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) and immunohistochemistry </plain></SENT>
<SENT sid="4" pm="."><plain>We established an experimental enzyme-linked immunosorbent assay (ELISA) to detect DK-β/γ in the serum of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients, and we compared the sensitivities of common diagnostic markers, carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, and serum p53 antibody (S-p53) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Immunohistochemical staining of <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colon tumor</z:e> tissue with anti-DK monoclonal antibody (mAb) revealed that DK-β/γ was more commonly expressed in the early stages of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (Tis-T1; i.e., <z:e sem="disease" ids="C0851135" disease_type="Neoplastic Process" abbrv="">cancer in situ</z:e>, intraepithelial or invasion of lamina propria [Tis]; <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> invades the submucosa [T1]) than in late-stage <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (T2-T4; i.e., <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> invades the muscularis propria [T2]; <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> invades through the muscularis propria into the subserosa, or into the nonperitonealized pericolic or perirectal tissues [T3]; <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> directly invades other organs or structures and/or perforates visceral peritoneum [T4]) </plain></SENT>
<SENT sid="6" pm="."><plain>Serum DK-β/γ levels were determined in 130 patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and 25 healthy volunteers </plain></SENT>
<SENT sid="7" pm="."><plain>Serum DK-β/γ was detected in 33.3% of patients with early <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (Tis-T1), which was higher than the rates for S-p53 (24.2%), CEA (9.1%), and CA19-9 (0%) </plain></SENT>
<SENT sid="8" pm="."><plain>The serum DK-β/γ test was complementary to the other marker tests </plain></SENT>
<SENT sid="9" pm="."><plain>Therefore, when the combined four-marker test (DK/CEA/CA19-9/S-p53) was carried out, the diagnostic sensitivity for Tis and T1 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> reached 60.6% </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Serum DK-β/γ is the most promising of the existing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> biomarkers for the diagnosis of early-stage <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>